Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients

Br J Haematol. 2002 Sep;118(3):817-20. doi: 10.1046/j.1365-2141.2002.03654.x.

Abstract

We evaluated microvessel density (MVD) in bone marrow biopsies (BM) from multiple myeloma (MM) patients after staining with anti-CD34 and anti-CD105 antibodies (mAbs). The anti-CD105 mAb was significantly more sensitive than the anti-CD34 mAb in visualizing blood vessels both in controls and MM samples. MVD was significantly higher in MM than in controls with both anti-CD34 and anti-CD105 mAbs. Patients with low CD34+ MVD survived longer than patients with higher MVD (P = 0.01), whereas there was no difference in survival between patients with low and high CD105+ MVD. Multivariate analysis confirmed the independent significant association between CD34+ MVD and survival (P = 0.001).

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / immunology
  • Antigens, CD
  • Antigens, CD34 / analysis*
  • Biomarkers, Tumor / analysis*
  • Endoglin
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Microcirculation
  • Middle Aged
  • Multiple Myeloma / blood supply*
  • Multivariate Analysis
  • Neovascularization, Pathologic / pathology*
  • Prognosis
  • Receptors, Cell Surface
  • Survival Rate
  • Vascular Cell Adhesion Molecule-1 / analysis

Substances

  • Antibodies, Monoclonal
  • Antigens, CD
  • Antigens, CD34
  • Biomarkers, Tumor
  • ENG protein, human
  • Endoglin
  • Receptors, Cell Surface
  • Vascular Cell Adhesion Molecule-1